Please Wait
Applying Filters...
menu
    • menu
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Left Arrow
    Right Arrow

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Avidicure is a Dutch biotech company developing AVC-Boosters, a novel class of dual agonistic, avidity-engineered antibodies designed to deliver potent and targeted monotherapy in oncology. These multifunctional molecules uniquely engage both innate and adaptive immunity, generating stronger and more coordinated immune responses than traditional therapies like checkpoint inhibitors or T-cell engagers. Supported by leading inve...
    Avidicure is a Dutch biotech company developing AVC-Boosters, a novel class of dual agonistic, avidity-engineered antibodies designed to deliver potent and targeted monotherapy in oncology. These multifunctional molecules uniquely engage both innate and adaptive immunity, generating stronger and more coordinated immune responses than traditional therapies like checkpoint inhibitors or T-cell engagers. Supported by leading investors including EQT Life Sciences and BioGeneration Ventures, Avidicure is advancing this next-generation antibody platform to overcome limitations of current cancer immunotherapies.

    List your booth number for exhibitions, ask us